1. Home
  2. JWSM vs AVIR Comparison

JWSM vs AVIR Comparison

Compare JWSM & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JWSM
  • AVIR
  • Stock Information
  • Founded
  • JWSM 2020
  • AVIR N/A
  • Country
  • JWSM United States
  • AVIR United States
  • Employees
  • JWSM N/A
  • AVIR N/A
  • Industry
  • JWSM Blank Checks
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • JWSM Finance
  • AVIR Health Care
  • Exchange
  • JWSM Nasdaq
  • AVIR Nasdaq
  • Market Cap
  • JWSM 302.5M
  • AVIR 311.4M
  • IPO Year
  • JWSM 2021
  • AVIR 2020
  • Fundamental
  • Price
  • JWSM $11.13
  • AVIR $3.83
  • Analyst Decision
  • JWSM
  • AVIR Sell
  • Analyst Count
  • JWSM 0
  • AVIR 1
  • Target Price
  • JWSM N/A
  • AVIR N/A
  • AVG Volume (30 Days)
  • JWSM 7.9K
  • AVIR 245.4K
  • Earning Date
  • JWSM 01-01-0001
  • AVIR 08-06-2024
  • Dividend Yield
  • JWSM N/A
  • AVIR N/A
  • EPS Growth
  • JWSM 75.00
  • AVIR N/A
  • EPS
  • JWSM 0.28
  • AVIR N/A
  • Revenue
  • JWSM N/A
  • AVIR N/A
  • Revenue This Year
  • JWSM N/A
  • AVIR N/A
  • Revenue Next Year
  • JWSM N/A
  • AVIR N/A
  • P/E Ratio
  • JWSM $39.75
  • AVIR N/A
  • Revenue Growth
  • JWSM N/A
  • AVIR N/A
  • 52 Week Low
  • JWSM $10.50
  • AVIR $2.77
  • 52 Week High
  • JWSM $11.25
  • AVIR $4.60
  • Technical
  • Relative Strength Index (RSI)
  • JWSM 54.05
  • AVIR 59.60
  • Support Level
  • JWSM $11.10
  • AVIR $3.54
  • Resistance Level
  • JWSM $11.14
  • AVIR $3.94
  • Average True Range (ATR)
  • JWSM 0.01
  • AVIR 0.17
  • MACD
  • JWSM 0.00
  • AVIR 0.06
  • Stochastic Oscillator
  • JWSM 75.00
  • AVIR 85.09

About JWSM Jaws Mustang Acquisition Corp.

Jaws Mustang Acquisition Corp is a blank check company. it is formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: